BeOne Medicines (ONC) Payables (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Payables data on file, last reported at $423.5 million in Q1 2026.

• On a quarterly basis, Payables rose 16.2% year-over-year to $423.5 million in Q1 2026; TTM through Mar 2026 was $423.5 million, a 16.2% increase from a year earlier, with the FY2025 full-year figure at $479.0 million, down 61.88% from the prior year.
• Payables for Q1 2026 stood at $423.5 million, down from $479.0 million in the prior quarter.
• Over the last five years, Payables for ONC reached as high as $1.3 billion in Q4 2024 and fell as low as $234.4 million in Q2 2022.
• Historically, Payables has averaged $427.2 million across 5 years, with a median of $333.0 million in 2024.
• Across the five-year window, Payables jumped 298.76% in 2024 and sank 61.88% in 2025, its largest moves.
• Year by year, Payables stood at $294.8 million in 2022, then increased by 6.9% to $315.1 million in 2023, then soared by 298.76% to $1.3 billion in 2024, then sank by 61.88% to $479.0 million in 2025, then dropped by 11.58% to $423.5 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $423.5 million in Q1 2026, $479.0 million in Q4 2025, and $1.2 billion in Q3 2025.